A ngiotensin II (Ang II), the major bioactive peptide of the renin-angiotensin system, was originally described as a potent vasoconstrictor. It is now recognized as a multifunctional hormone influencing many cellular processes, including cell growth, apoptosis, migration, inflammation, and fibrosis. 1,2 Under pathological conditions, the vasoconstrictor, mitogenic, proinflammatory, and profibrotic actions of Ang II contribute to altered vascular tone, structural remodeling, and endothelial dysfunction. [3] [4] [5] [6] Thus, Ang II plays a key role in the pathogenesis of cardiovascular diseases.
AT 1 R Gene Structure
To initiate the investigations into the mechanisms by which AT 1 R expression is regulated, the AT 1 R gene has been cloned from a variety of species. Uniquely, the rodent genome harbors 2 distinct AT 1 R genes: AT 1A R and AT 1B R. 9 -15 The AT 1A R gene has been localized to chromosomes 17 and 13 of the rat and mouse, respectively, whereas the AT 1B R gene has been localized to chromosomes 2 and 3 of the rat and mouse, respectively. 14, 15 It has been suggested that both receptor subtypes are pharmacologically and functionally identical 16 -20 ; however, both of these receptor subtypes are expressed in a tissue-specific manner and seem to be differentially regulated. 12, 16, 20 In vivo studies suggest that the AT 1A R is primarily responsible for the regulation of blood pressure and cardiovascular function. 21 These conclusions were based on the observation that AT 1A R knockout (AT 1 R Ϫ/Ϫ ) mice were found to exhibit low blood pressure and attenuated Ang II pressor response. [22] [23] [24] However, recent studies suggest that the AT 1B R predominantly mediates Ang II-induced contraction in mouse abdominal aorta, femoral artery, and mesenteric resistance vessels. 25, 26 The rat AT 1A R (rAT 1A R) gene is composed of 3 exons and spans Ͼ40 kb ( Figure 1 ). [27] [28] [29] Exons 1 and 2 constitute the 5Ј-untranslated region (UTR) sequence, whereas exon 3 harbors the uninterrupted open reading frame (ORF) for the rAT 1A R and the entire 3Ј-UTR, which contains 2 polyadenylation sequences. Primer extension and S1 mapping identified a single transcription initiation site 31 bp downstream of a TATA sequence. 29 The rAT 1B R gene is also composed of 3 exons, with exons 1 and 2 encoding the 5Ј-UTR and the third exon harboring the ORF. 30 Unfortunately, there is little additional information regarding the regulation of the rAT 1B R gene.
In contrast to rodents, the human genome harbors only a single AT 1 R gene. Curnow et al 31 mapped the human AT 1 R (hAT 1 R) gene to chromosome 3q and found no evidence of related hAT 1 R genes on other chromosomes. In support of this conclusion, Southern blot analyses confirmed the presence of only a single AT 1 R gene 32 in the human genome. The hAT 1 R gene is composed of Ն4 exons and spans Ͼ60 kb ( Figure 1 ). [32] [33] [34] [35] Exons 1, 2, and 3 constitute the 5Ј-UTR sequence, whereas exon 4 harbors the entire uninterrupted ORF for the hAT 1 R. RNA ligase-mediated rapid amplification of cDNA ends 36 and primer extension experiments 33 demonstrated that there is 1 major transcription initiation start site located 25 bp downstream of a consensus TATA box element.
Regulation of AT 1 R Expression by Alternative Splicing
While, characterizing the hAT 1 R gene it was demonstrated that Ն4 alternatively spliced hAT 1 R mRNAs were transcribed in human tissues ( Figure 1) . 33, 34 The hAT 1 R mRNA splice variants were composed of the following exons: exons 1 and 4; exons 1, 2, and 4; exons 1, 3, and 4; and exons 1, 2, 3, and 4; therefore, alternatively spliced hAT 1 R mRNAs differ only in the inclusion or exclusion of exon 2 and/or 3 (reviewed in Reference 37). Splice variants that harbor exon 2 are functionally interesting because they contain 2 upstream AUG start codons (Figure 1) , 34, 38 which are predicted to generate upstream ORFs (uORFs) of different lengths. PCR analysis demonstrated that hAT 1 R mRNA splice variants, which included exon 2 (ie, exons 1, 2, and 4), were composed of Ն30% of the total hAT 1 R mRNA transcripts expressed in a given tissue; this suggests that this splice variant is physiologically important. 34,38 -40 Curnow et al 34 and Warnecke et al 38 demonstrated that the presence of exon 2 inhibited the translation of the hAT 1 R mRNAs in vitro and decreased luciferase activity in reporter gene assays. Martin et al 40 extended these earlier findings and demonstrated that the inclusion of exon 2 in hAT 1 R mRNA transcripts dramatically reduced hAT 1 R protein levels and significantly attenuated Ang II responsiveness. These results also suggested that both AUGs present in exon 2 could initiate translation and, therefore, reduce the number of ribosomes that initiated translation at the downstream hAT 1 R ORF harbored in exon 4. However, the importance of the 2 upstream ORFs in vivo remains undefined.
Alternative splicing can also occur in 1 of the 2 identified rat AT 1 R genes, the rAT 1A R gene (Figure 1 ). [41] [42] [43] [44] When the rAT 1A R gene is transcribed, 2 mRNA transcripts are synthesized, 1 harboring exons 1 and 3 and another harboring exons 1, 2, and 3. It was shown that AUGs/uORFs present in exon 2 of the rAT 1A R mRNA inhibited reporter gene assays. [41] [42] [43] [44] Zhang et al 42 and Ji et al 43 extended these studies by demonstrating that the inclusion of exon 2 in rAT 1A R mRNAs inhibited AT 1 R expression and AT 1 R-mediated signaling. Importantly, the presence of exon 2 did not modulate rAT 1A R mRNA stability and, like the hAT 1 R mRNA splice variants (ie, exons 1, 2, and 4 and exons 1 to 4), both AUGs harbored in the rat exon 2 were involved in the inhibition of receptor expression.
The hAT 1 R mRNA splice variants, which harbor exon 3 (ie, exons 1, 3, and 4 and exons 1 to 4 transcripts), are also of particular interest, because exon 3 contains an AUG start codon, which is in-frame with the downstream ORF located in exon 4. 34, 37, 40 When these transcripts are translated, a novel hAT 1 R isoform ("long" hAT 1 R) is synthesized, which is composed of an additional 32 amino acids at the N-terminus. Martin et al 40 demonstrated that the long receptor isoform has a 3-fold diminished affinity for Ang II. Therefore, depending on the concentration of Ang II, the percentage of the long and short (ie, synthesized from exons 1 and 4 or exons 1, 2, and 4 hAT 1 R mRNA transcripts) hAT 1 R isoforms activated will differ; thus, the potency of the Ang II response will vary. Ultimately, Ang II responsiveness can be fine-tuned by regulating the relative synthesis of the long and short hAT 1 R Figure 1 . A schematic representation of the rat and human AT 1 R genes and their potential to generate AT 1 R mRNA splice variants. ATGs denote the beginning of uORFs. Although the AT 1 R gene structure is not known for most animals, a highly homologous 5Ј-UTR exon 2-like sequence has been identified in 8 additional species. 37, 40 All of these sequences harbor uORFs and, therefore, may represent a common AT 1 R translational inhibitory mechanism. Currently, it is not known whether the rAT 1B R gene undergoes alternative splicing. Only the human and primate genomes harbor a 5Ј-UTR exon 3 sequence. 37 isoforms in a given tissue. PCR analysis has shown that this splice variant is relatively rare, with the exception of adrenal tissue, where exon 1, 3, and 4 mRNAs composed Ϸ50% of the hAT 1 R alternatively spliced mRNAs. 40 Interestingly, sequence comparisons between species have demonstrated that an exon 3-like sequence was only conserved in humans and primates suggesting that this fine-tuning mechanism does not occur in all species. 37 Because the inclusion or exclusion of exon 2, exon 3, or both has a profound influence on the control of AT 1 R density and function, it is important to investigate whether alternative splicing can be regulated. It is obvious from PCR studies that AT 1 R mRNA splice variants are regulated in a tissue-specific manner. 34, 37, 39, 40 In addition, data from Warnecke et al 38 suggested that hAT 1 R mRNA splicing events may be regulated by pathophysiological stimuli. These investigators demonstrated that, in normal and failing human heart tissue, the exon 1,4 and exon 1,2,4 splice variants represented 93% to 98% of all hAT 1 R mRNAs. The ratio of hAT 1 R mRNA transcripts harboring exon 2 versus those lacking exon 2 was decreased in atria from failing hearts compared with control atria. Similar results were obtained when comparing endomyocardial biopsy samples from patients with normal and impaired left ventricular function and when comparing the left ventricle of explanted normal hearts with those of 14 end-stage failing explanted hearts. 38 The increased expression of the exon 1,4 splice variant, and the decreased levels of the exon 1,2,4 splice variant would result in enhanced hAT 1 R levels and signaling events; hence, it could be argued that this dysregulation plays a role in mediating heart failure. Alternatively, increased hAT 1 R density and function may be needed to improve cardiac function in patients with heart failure.
In support of the hypothesis that physiological/pathophysiological stimuli may modulate hAT 1 R mRNA alternative splicing events, Martin et al 40 demonstrated that transforming growth factor-␤ 1 treatment of human lung fibroblasts upregulated exon 1,4 mRNAs 2-fold, and exon 1,2,4 transcripts were increased 6-fold. In contrast, the exon 1,3,4 hAT 1 R mRNA splice variants were downregulated 18-fold. Because enhanced AT 1 R expression can be detrimental, 5 the TGF-␤ 1 upregulation of hAT 1 R mRNAs, which include exon 2, may represent a mechanism to limit the pathogenicity of hAT 1 Rs. In addition, Cowling et al 44 demonstrated that cytokine treatment of rat cardiac fibroblasts upregulated all of the rAT 1A R splice variants, with exon 1,3 mRNAs showing the greatest increase. The increased expression of the exon 1,3 rAT 1A R mRNA splice variant would lead to enhanced receptor density and signaling, thereby implicating a role in mediating cardiac fibrosis.
In conclusion, these studies demonstrate that alternative splicing can be regulated and that, ultimately, the relative abundance of each AT 1 R mRNA splice variant controls AT 1 R protein levels and, thus, consequently affects the potency of the Ang II response. Therefore, dysregulation of AT 1 R mRNA splicing mechanisms could play a role in mediating cardiovascular disease. Currently, very little is known regarding the regulation of these mechanisms, and clearly more studies are needed to address this important question. It appears that the primary mechanism by which alternative splicing regulates AT 1 R expression is through a translational mechanism that involves the uORFs contained in exon 2.
AT 1 R Transcriptional Regulation
A large number of studies have shown that a wide range of physiological and pathophysiological stimuli modulate AT 1 R expression in a number of cell types and tissues (reviewed in Reference 45) . Although the molecular mechanisms by which the AT 1 R density is regulated are not completely elucidated, some of these stimuli have been shown to modulate AT 1 R gene transcription rates (Figure 2) . Examples of such agonists are Ang II, 46, 47 interferon-␥, 48 growth factors, 49 statins, 50, 51 NO, 52 thyroid hormone, 53 all-trans-retinoic acid, 54 peroxisome proliferator-activated receptor (PPAR)-␥, and activator ligands (ie, 15-deoxy-␦ 12,14 -prostaglandin J 2 , troglitazone, rosiglitazone, and pioglitazone). [55] [56] [57] All of these act by transcriptionally suppressing the rAT 1A R gene in cultured rat VSMCs. In contrast, glucocorticoids, 58 -60 insulin-like growth factor, 61 interleukin (IL)-6, 62 and progesterone 63 induced an upregulation of rAT 1A R expression in VSMCs by a transcrip- Figure 2 . Transcriptional regulation of AT 1 R gene expression. C-reactive protein, cyclosporine, glucocorticoids, growth hormone, interleukins (IL-1␤ and IL-6), insulin-like growth factor-1, progesterone, and TNF-␣ all transcriptionally activate the AT 1 R gene. The increased transcription rates result in enhanced AT 1 R steady-state mRNA levels, which, in turn, lead to increased AT 1 R expression. On activation by Ang II, augmented AT 1 R density subsequently leads to increased signaling (eg, increased reactive oxygen species release), which, in turn, may lead to vascular remodeling, endothelial dysfunction, inflammation, atherosclerosis, and hypertension. In contrast, interferon ␥ (IFN␥), NO, PPAR␥, retinoic acid, statins, and thyroid hormone all decrease AT 1 R gene transcription rates. These stimuli lead to decreased AT 1 R expression and signaling and, therefore, reduce cellular events that lead to cardiovascular disease.
tional mechanism. In addition, it has been demonstrated that tumor necrosis factor (TNF)-␣, IL-1␤, and dexamethasone can transcriptionally enhance the rAT 1A R gene in cardiac fibroblasts. 64 -66 Several studies have been published investigating the regulation of the hAT 1 R gene in human cells. Avdonin et al 67 and Wang et al 68 
Because rodents harbor 2 AT 1 R genes and humans only harbor 1, it has been debated whether or not these genes will be regulated by the same mechanisms. When the hAT 1 R promoter region was compared with the rAT 1A R and rAT 1B R promoter sequences, very little homology was found. Therefore, it was concluded that the mechanisms that govern the rodent AT 1 R genes cannot be assumed to regulate the hAT 1 R gene. 71 In support of this conclusion, it was demonstrated that Sp1 and Sp3 are predominantly responsible for regulating the basal expression of the hAT 1 R in all of the cell types investigated, including human VSMCs. 36, [72] [73] [74] In contrast, MEF-2 heterodimers 75 and, to a lesser degree, Sp1 55, 76, 77 are required for basal expression of the rAT 1A R gene.
Transcriptional Suppression of the AT 1 R Gene
Although a variety of physiological stimuli regulate AT 1 R density by modulating AT 1 R mRNA transcription rates, the exact mechanisms of transcriptional control are poorly understood ( Figure 2 ). The best-characterized mechanism to date is the PPAR-␥-mediated transcriptional suppression of the rAT 1A R gene. [55] [56] [57] PPAR-␥ belongs to the nuclear receptor family of ligand-activated transcription factors, which also includes PPAR-␣ and PPAR-␤/␦. PPARs heterodimerize with the retinoid X receptor and then act as transcription factors to modulate the functions of many target genes. 78 All of the PPARs are expressed in VSMCs where they exert antiatherogenic, anti-inflammatory, and vasculoprotective actions. Activators of PPAR-␣ (fibrates) and PPAR-␥ (thiazolidinediones or glitazones) antagonize Ang II effects in vivo and in vitro, in part by decreasing the expression level of the AT 1 R. [55] [56] [57] 79, 80 Sugawara et al 55 demonstrated that a GC-box-related sequence within the Ϫ58/Ϫ34 bp region of the rAT 1A R promoter was responsible for the PPAR-␥ suppression. Sp1 overexpression stimulated rAT 1A R gene transcription via the GC-boxrelated sequence, which was inhibited by additional PPAR-␥ overexpression. Furthermore, glutathione S-transferase pulldown assays demonstrated that PPAR-␥ and Sp1 directly interacted with each other. It has also been shown that the MAPK pathway and coactivator CREB-binding protein, CBP/p300, may antagonize PPAR-␥ regulation of the rAT 1A R gene. 57 Interestingly, activation of the MAPK pathway and CBP/ p300 has been reported recently to be atherogenic. 81, 82 In summation, these findings suggest that activated PPAR-␥ suppresses rAT 1A R gene expression at the transcriptional level by inhibiting Sp1 binding activity via protein-protein interactions. In contrast, PPAR-␥ phosphorylation by the MAPK pathway and CBP enhanced activity of Sp1. As a result, gene transcription rates of rAT 1A R are increased. Thus, PPAR-␥ ligands may inhibit Ang II-induced cell growth and hypertrophy in VSMCs by inhibiting AT 1 R expression. Such implications could be beneficial for treatment of diabetic patients with hypertension and atherosclerosis.
In addition to their cholesterol-lowering activities, statins exert pleiotropic anti-inflammatory effects and improve endothelial function. 83, 84 The exact mechanisms involved in the anti-inflammatory properties of statins are unresolved; although it has now been demonstrated that PPAR-␣, PPAR-␤/␦, and PPAR-␥ may mediate these effects. [85] [86] [87] Importantly, Takeda et al 54 have demonstrated that cerivastatin and fluvastatin transcriptionally repressed the rAT 1A R gene in VSMCs. Although rAT 1A R promoter analysis was not performed in this study, VSMCs are known to express all of the PPAR isoforms; therefore, rAT 1A R transcriptional repression by statins may result from a similar mechanism as described with PPAR-␥ downregulation of rAT 1A R expression.
Ichiki et al 51 also found that the first 61 bp of the rAT 1A R promoter were necessary for NO suppression of transcription. Two DNA binding proteins were observed by electrophoretic mobility-shift assays, and 1 of these binding proteins was decreased with NO stimulation. NO is known to decrease Sp1 binding to GC elements on other genes 88, 89 ; therefore, one could speculate, as described for PPAR-␥ ligands, that reduced Sp1 binding to the GC-box-related sequence is responsible for the transcriptional suppression of the rAT 1A R gene. This inhibitory mechanism of AT 1 R gene expression may be partially implicated in the antiatherogenic properties of NO.
Currently, it is not known whether the GC-box described in the hAT 1 R promoter region 36, [72] [73] [74] also plays a critical role in mediating a PPAR/Sp1 regulatory system in human cells. It appears, however, that fibrates, glitazones, and statins can also transcriptionally repress the expression of the hAT 1 R gene in H295-R cells (T.S. Elton, unpublished observation, 2006).
In conclusion, these studies suggest that PPAR activators, statins, and the anti-inflammatory and anti-atherogenic properties of NO result, in part, by downregulating AT 1 R density. The decrease in AT 1 R expression, therefore, diminishes the potency of the Ang II response (ie, reactive oxygen species generation and subsequent oxidative damage). Recently, it was demonstrated that the AT 1 R blockers irbesartan and telmisartan are not only AT 1 R antagonists but PPAR-␥ activators. 90 Therefore, PPAR-␥-activating AT 1 R blockers may be superior to nonactivating AT 1 R blockers in the clinical setting, because these antagonists may also reduce AT 1 R expression levels. These studies also support the theory that there is a mechanistic rationale for the use of "combination therapies" in treating cardiovascular diseases.
Transcriptional Activation of the AT 1 R Gene
Because the overexpression of the AT 1 R is thought to play a role in cardiovascular disease, 5 there is great interest in understanding the transcriptional mechanisms that activate the AT 1 R gene (Figure 2) . Recently, it was demonstrated that the proinflammatory cytokines TNF-␣ and IL-1␤ upregulated rAT 1A R density on rat cardiac fibroblasts. 44, 64, 65 Cowling et al 65 used pharmacological inhibitors and a degradation-resistant mutant inhibitor of nuclear factor B (NF-B)-␣ to demonstrate that the transcription factor, NF-B, was necessary for cytokine-induced rAT 1A R upregulation. TNF-␣ treatment did not alter rAT 1A R mRNA stability. In addition, RT-PCR of heterogeneous nuclear RNA showed increased rAT 1A R heterogeneous nuclear RNA levels. 65 These results suggested that cytokines increased rAT 1A R density in cardiac fibroblasts by a transcriptional mechanism. Because both TNF-␣ and IL-1␤ are known to activate NF-B, these investigators hypothesized that NF-B binding sites present in the rAT 1A R promoter region must help in mediating this response. Cowling et al 44 subsequently demonstrated that 2 cis-response elements located at Ϫ365/Ϫ355 bp and Ϫ2540/ Ϫ2530 bp bound NF-B and could transactivate a minimal promoter. These investigators concluded that these proinflammatory cytokines activated NF-B, which resulted in enhanced AT 1 R transcription rates. These data have been extrapolated to propose that the augmented AT 1 R levels would increase Ang II-induced signaling, which may lead to increased diastolic stiffness and, in turn, cause contractile dysfunction by enhancing cardiac fibrosis. 91, 92 The rAT 1A R density is increased in several animal models of cardiac myocyte hypertrophy suggesting that these receptors may play a role, in part, in mediating these pathological events. 93 To investigate whether a transcriptional mechanism was involved, an rAT 1A R promoter/reporter construct was injected into adult rat hearts subjected to an acute pressure overload. 94 Importantly, pressure overload increased expression from the rAT 1 R promoter. The induced expression was blocked by mutation of either a consensus-binding site for AP-1 (Ϫ395/Ϫ375 bp) or GATA (Ϫ290/Ϫ273 bp) transcription factors in the rAT 1A R promoter; however, these mutations had no effect on basal expression. In addition, these investigators demonstrated that a Fos-JunB-JunD complex and GATA-4 interacted with the AP-1 and GATA sites located within the rAT 1A R promoter region. Administration of the angiotensin-converting enzyme inhibitor captopril decreased pressure overload-induced expression, whereas Ang II treatment of transfected cardiomyocytes increased rAT 1A R promoter expression. These results conclusively suggest that Ang II, working through the induction of immediate early genes, activates expression of the rAT 1A R gene, thus providing a potential positive feedback loop for potentiation of Ang II effects.
Glucocorticoids are involved in the regulation of blood pressure, and enhanced vascular responsiveness has been considered to be 1 of the major contributing factors. 95 Glucocorticoids increase vascular sensitivity to Ang II by enhancing promoter activity of the rAT 1A R gene, which, in turn, leads to increased receptor levels. 58 -60 Three putative glucocorticoid response elements (GREs) were identified in the rAT 1A R promoter; however, only 1 GRE at Ϫ770/Ϫ756 bp was found to be responsive to dexamethasone. Supershift assays demonstrated that glucocorticoid receptors could specifically interact with this rAT 1A R promoter sequence. 59 In contrast, no consensus GREs are present in the hAT 1 R promoter; however, there are a number of GRE half-sites (GRE 1/2s) harbored in this gene. 71 This observation suggests that glucocorticoid-induced upregulation of the hAT 1 R gene may be mediated by multiple GRE 1/2s 96, 97 or a GRE 1/2 plus an additional accessory element. 98 Unfortunately, very few studies have been published investigating the mechanisms by which stimuli transcriptionally augment the hAT 1 R gene. Wyse et al 69 demonstrated that growth hormone increased the rate of transcription of the hAT 1 R gene through a sequence harbored at Ϫ161/Ϫ149 bp in human proximal tubule cells. These investigators also demonstrated that an 18-kDa protein specifically interacted with this site and that protein binding was increased with growth hormone activation. Finally, they determined that epidermal growth factor, platelet-derived growth factor, and insulin activated this binding protein.
Recently, Li et al 99 demonstrated that, in cultured human coronary artery endothelial cells, oxidized low-density lipoprotein (LDL) upregulated hAT 1 R expression by a mechanism that involved NF-B. However, these investigators did not specifically investigate whether oxidized LDL enhanced hAT 1 R expression by a transcriptional and/or a posttranscriptional mechanism. Computer analysis of the hAT 1 R promoter region demonstrated that it harbored a single consensus NF-B site at Ϫ1240/Ϫ1228 bp. Therefore, it is plausible that oxidized LDL does regulate hAT 1 R expression by a transcriptional mechanism and suggests that the hAT 1 R gene could also be regulated by a cytokine/NF-B-mediated mechanism described by Cowling et al. 44 In conclusion, little is known regarding the mechanisms that enhance AT 1 R transcriptional rates. Some important cis-regulatory elements and trans-factors have been identified; however, nothing is known regarding the factors involved in mediating the insulin-like growth factor-1, 61 IL-6, 62 and C-reactive protein 68 transcriptional activation of the AT 1 R gene. This is a critical deficiency in our understanding, because these factors all play a role in mediating cardiovascular disease.
Regulation of AT 1 R Expression by Modulating mRNA Half-Life
It is now well established that a number of stimuli can regulate AT 1 R expression levels by modulating AT 1 R mRNA stability or half-life ( Figure 3 ). For example, Ang II, 100 cAMP stimulating agents, 101 estrogens, 63 growth factors, 49 and thyroid hormone 53 decrease rAT 1A R density by increasing rAT 1A R mRNA decay rates (ie, decrease in mRNA stability) in rat VSMCs (Figure 3) . Inversely, insulin, 102 LDL, 103 and progesterone 63 increase rAT 1A R density by decreasing rAT 1A R mRNA decay rates (ie, increase mRNA stability) in rat VSMCs (Figure 3 ). Investigating the mechanisms by which Ang II leads to the destabilization of the rAT 1A R mRNA in VSMCs, it was demonstrated that Ang II stimulation induces proteins to bind specifically to an AUUUUA sequence located at the distal end of the rAT 1A R mRNA. 100, 104 One of these proteins was purified by multiple chromatographic steps and identified by mass spectroscopy to be calreticulin. 105 Ang II stimulation was shown to induce the phosphorylation of calreticulin, which enabled this protein to bind to the 3Ј-UTR of the rAT 1A R mRNA, and subsequently accelerated the decay of this mRNA. Interestingly, hAT 1 R mRNAs also harbor an identical AUUUUA sequence localized to the same region as described in the rAT 1A R mRNA 3Ј-UTR. 31 Therefore, calreticulin may also play a role in regulating the Ang II-mediated decay of hAT 1 R mRNAs in human cells.
Because the studies described above were performed using transcriptional inhibitors (ie, actinomycin D or 5,6-dichloro-1␤-D-ribofuranosylbenzimidazole) that have multiple nonspecific effects, Xu and Murphy 106 used a tetracyclinesuppressible promoter to express recombinant rAT 1A R mRNA mimics and measured decay rates without the use of these inhibitors. They demonstrated that Ang II and PDGF did not increase rAT 1A R mRNA decay rates and suggested that only a transcriptional mechanism was responsible for the decreased rAT 1A R mRNA levels. 106 In contrast, however, it was shown that forskolin downregulated rAT 1A R expression through a posttranscriptional mechanism. Interestingly, these investigators demonstrated that the forskolin response was mediated by the 5Ј-UTR, and not the 3Ј-UTR, of the rAT 1A R mRNA. The cis-acting element(s) or trans-factor(s) responsible for this activity were not identified.
In conclusion, the mechanisms that regulate AT 1 R mRNA stability are still poorly understood. The importance of calreticulin in Ang II-mediated decay of AT 1 R mRNAs has not been confirmed and remains controversial, because it is not clear how this protein plays a role in mRNA degradation. To date, no studies have been published that investigate the mechanisms by which insulin 102 and LDL 103 increase mRNA stability. Clearly more studies are needed to define these mechanisms, because these stimuli increase AT 1 R expression levels and, thus, result in enhanced Ang II signaling. Therefore, to some degree, increased AT 1 R mRNA stability may account for why insulin and LDL are often associated with hypertension and arteriosclerosis. Furthermore, because estrogen destabilizes AT 1 R mRNAs, this may explain in part the association between estrogen deficiency (ie, which would result in increased AT 1 R levels) and hypertension and atherosclerosis.
Perspectives
The outlined transcriptional and posttranscriptional mechanisms governing AT 1 R expression are extremely complicated and suggest the crucial need to fine tune Ang II responsiveness by modulating AT 1 R density. As additional studies are conducted, the complexity of AT 1 R gene regulation is certain to expand. In support of this hypothesis, a novel posttranscriptional hAT 1 R regulatory mechanism was identified recently that involved the specific interaction of micro-RNAs with hAT 1 R mRNAs. 107 Clearly more studies are needed to validate and to determine the impact of micro-RNAs on AT 1 R gene expression. In conclusion, aberrant expression of the AT 1 R can result from the dysregulation of any of the transcriptional and posttranscriptional mechanisms described herein and may lead to cardiovascular disease. Therefore, it is important to continue these lines of investigation with the hope that this new knowledge may result in the development of novel therapies to treat cardiovascular disease. Regulation of AT 1 R expression by controlling mRNA stability. Insulin, LDL, and progesterone augment AT 1 R expression by decreasing AT 1 R mRNA decay rates (ie, increase mRNA stability). On activation of Ang II, the enhanced receptor levels may lead to pathological cellular events (eg, augmented reactive oxygen species release), which may result in vascular remodeling, endothelial dysfunction, inflammation, atherosclerosis, and hypertension. In contrast, cAMP stimulating agents, estrogens, growth factors, and thyroid hormone decrease AT 1 R density by increasing AT 1 R mRNA decay rates (ie, decrease in mRNA stability). Therefore, these stimuli attenuate AT 1 R-mediating signaling and, therefore, reduce cellular events that lead to cardiovascular disease. It has been demonstrated that specific cis-elements harbored in the 5Ј-and 3Ј-UTR of AT 1 R mRNAs may be responsible for regulating mRNA stability.
